Back

Predicted change in 10-year cardiovascular risk one year after initiation of bempedoic acid-based therapy in the MILOS study

31 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Lipids and cardiovascular risk (2) Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Klaus G Parhofer

Ludwig Maximilians University, Munich (Germany)

6 More presentations in this session

Presentation thumbnail
Lipid markers and age differences in atherosclerotic cardiovascular disease risk
Miss H. Su (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Contemporary paediatric lipid percentiles in 5–14-year-olds: a population-based cross-sectional analysis
Doctor J. Krefting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Risk-weighted apolipoprotein B in patients hospitalized for acute coronary syndrome: characteristics associated with discordance with measured apolipoprotein B levels.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides Video
Presentation thumbnail
Impact of atherogenic lipoproteins and inflammatory markers on silent atherosclerosis
Doctor N. Sandau (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Current non-HDL cholesterol treatment target insufficiently captures residual cardiovascular risk in very-high risk patients
Doctor M. Hansen (Aarhus, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids and cardiovascular risk (2)

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients
26 August 2022
thumbnail
Congress Presentation
Cardiovascular risk assessment in multiple myeloma patients undergoing carfilzomib therapy: a new risk prediction model for cardiovascular adverse events
12 December 2020
thumbnail
Congress Presentation
Prediction of lifetime cardiovascular risk and individual lifetime treatment benefit in four European risk regions: geographic recalibration of the LIFE-CVD model
28 August 2022
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
19 February 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources